Table 1 Descriptive characteristics of included study in this systematics review and meta-analysis for treatment recovery of admitted COVID-19 patients
First Author name | Place | Study periods | Comorbidity Status | PublicationDD/MM/YY | Phase of COVID-19 | Study setting | Design | Male/Female | Mean age (卤) Y | Mean recovery time /days | Death | Cured | Self- discard/ T/out | Total | Quality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saro Abdella et.al [1] | AA | 18/03/2020 to 27/06/ 2020 | Yes =41 | 30/12/ 2020 | Phase 1 | Hospital | Retrospective | Male =208 | 34 | 19(卤9.5) | 20 | 286 | NR | 306 | 3 |
No =265 | Female=98 | ||||||||||||||
Tadesse Tolossa et.al [2] | Oromia | 29/03/2020 to 30/09/ 2020 | Yes =21 | 10/06/2021 | Phase 1 | Hospital | Retrospective | Male =155 | 36.8 | 18(卤8) | 36 | 227 | NR | 263 | 3 |
No =206 | Female=72 | ||||||||||||||
Haftom Temesgen et.al [3] | Tigray | 7 /5/2020 to 28/10/2020 | Yes =40 | 11/08/2022 | Phase 1 | COVID-19 Rx centers | Retrospective | Male =69 | 35(卤33) | 18(卤16) | 56 | 83 | NR | 139 | 3 |
No =99 | Female= 17 | ||||||||||||||
Lire Lemma Tiror et.al 2022 [4] | SNNPR | 30/5 2020 to 15/10/ 2021 | Yes =143 | 11/ 8/2022 | Phase 2 | COVID-19 Rx centers | Retrospective | Male =493 | 30(卤25) | 10(卤8.0) | 94 | 751 | NR | 845 | 3 |
No =608 | Female =258 | ||||||||||||||
Anteneh Mengistet.al 2022 [5] | Amhara | 13/03/2020 to 30 /02 2021 | Yes =156 | 12/4/ 2022 | Phase 2 | COVID-19 Rx centers | Retrospective | Male =348 | 41(卤23) | 11(卤5.01) | 58 | 540 | 7 | 622 | 3 |
No =466 | Female=274 | ||||||||||||||
Serkalem Tsegay et.al [6] | Oromia | 7/08/2020 to 7/02/2022 | Yes =287 | 17 /11/ 2022 | Phase 3 | Hospital | Retrospective | Male =191 | 38.5(卤16.) | 11.1(卤1.3) | 13 | 276 | 7 | 300 | 3 |
No =9 | Female =109 | ||||||||||||||
Desiyalew-Habtamu et.al [7] | Amhara | 1/11/2022to 15/11/2021 | Yes =153 | 12/10/2023 | Phase 3 | Hospital | Retrospective | Male =302 | 57.5(卤3) | 9(卤 7.0) | 37 | 397 | 18 | 452 | 3 |
No =299 | Female= 150 | ||||||||||||||
Maru Zewdu et.al [8] | Benishangul | 01/02 2021 to01/07/ 2021 | Yes =116 | 05/11/2023 | Phase 3 | COVID-19 Rx centers | Retrospective | Male=172 | 45.2(卤 12.2) | 16(卤5.5) | 76 | 258 | NR | 334 | 2 |
No =218 | Female=162 | ||||||||||||||
Saro Abdella et.al [9] | AA | 18/03/2020 to20/09/ 2020 | Yes =36 | 06/08/2021 | Phase 1 | Hospital | Prospective | Male= 94 | 42(卤17) | 16(卤13) | NR | 105 | NR | 124 | 2 |
No =88 | Female= 30 | ||||||||||||||
Gemechu Churiso et.al [10] | SNNR | 01/09/ 2020 to01/07/ 2021 | Yes =176 | 04/03/ 2022 | Phase 3 | Hospital | Retrospective | Male= 123 | 47(卤狈搁) | 5(卤2.3) | 49 | 171 | NR | 220 | 3 |
No =44 | Female= 97 | ||||||||||||||
Tigist W. Leulseged [11] | AA | 01/6/2020to 01/9/2020 | Yes =454 | 09/10/2021 | Phase 1 | COVID-19 Rx centers | Prospective | Male= 557 | 41(卤 18.2) | 14(卤?) | 71 | 1202 | 72 | 1345 | 3 |
No =891 | Female=778 | 听 | |||||||||||||
Getaneh Atikilt et.al [12] | Amhara | 30/12/2020 to01/ 04/2021 | Yes=70 | 23/05/2022 | Phase 3 | COVID-19 Rx centers | Prospective | Male= 163 | 41.2 (卤 19) | 5(卤2.2) | 80 | 115 | 5 | 202 | 2 |
No=132 | Female=39 | ||||||||||||||
Abdene Weya Kaso et.al [13] | Oromia | 1/6/2020, to 10/30/ 2021 | Yes =245 | 13/12/2021 | Phase 1 | Hospital | Retrospective | Male =244 | 43 (卤 19) | 13(卤8) | 42 | 354 | 12 | 422 | 3 |
No=177 | Female =178 | ||||||||||||||
Samrawit Fantaw et.al [14] | Sidama | 01/5/2020, to 30/5/ 2022. | Yes = 204 | 29/ 10/2023 | Phases 3 | COVID-19 Rx centers | Retrospective | Male =712 | 43.1 卤20.3) | 14(卤8) | 181 | 715 | 29 | 1038 | 3 |
No=500 | Female= 326 | ||||||||||||||
Ali B. Anteneh Et.al [15] | Sidama | 24/9/2020, to 26/11/ 2021 | Yes =395 | 07/01/2025 | Phases 3 | Hospita | Retrospective | Male =515 | NR | 12(卤.3) | NR | 595 | NR | 804 | 2 |
No=409 | Female=289 | ||||||||||||||
Angesom weldu et.al [16] | South west region | 2/11/ 2020 | Yes =39 | 03/6/2023 | Phases 1 | Hospital | Retrospective | Male =145 | 29 (卤17) | 10(卤8-10) | 5 | 229 | 9 | 260 | 3 |
No=221 | Female=115 |